全文获取类型
收费全文 | 1607篇 |
免费 | 94篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 43篇 |
妇产科学 | 29篇 |
基础医学 | 172篇 |
口腔科学 | 25篇 |
临床医学 | 156篇 |
内科学 | 284篇 |
皮肤病学 | 27篇 |
神经病学 | 135篇 |
特种医学 | 73篇 |
外科学 | 250篇 |
综合类 | 11篇 |
一般理论 | 2篇 |
预防医学 | 155篇 |
眼科学 | 14篇 |
药学 | 201篇 |
中国医学 | 6篇 |
肿瘤学 | 116篇 |
出版年
2024年 | 4篇 |
2023年 | 18篇 |
2022年 | 21篇 |
2021年 | 40篇 |
2020年 | 27篇 |
2019年 | 36篇 |
2018年 | 31篇 |
2017年 | 26篇 |
2016年 | 22篇 |
2015年 | 27篇 |
2014年 | 33篇 |
2013年 | 66篇 |
2012年 | 91篇 |
2011年 | 96篇 |
2010年 | 65篇 |
2009年 | 50篇 |
2008年 | 85篇 |
2007年 | 91篇 |
2006年 | 78篇 |
2005年 | 87篇 |
2004年 | 71篇 |
2003年 | 79篇 |
2002年 | 70篇 |
2001年 | 63篇 |
2000年 | 44篇 |
1999年 | 53篇 |
1998年 | 12篇 |
1997年 | 17篇 |
1996年 | 10篇 |
1995年 | 8篇 |
1994年 | 6篇 |
1993年 | 7篇 |
1992年 | 32篇 |
1991年 | 31篇 |
1990年 | 19篇 |
1989年 | 27篇 |
1988年 | 19篇 |
1987年 | 26篇 |
1986年 | 20篇 |
1985年 | 10篇 |
1984年 | 16篇 |
1983年 | 6篇 |
1979年 | 6篇 |
1978年 | 6篇 |
1975年 | 4篇 |
1971年 | 5篇 |
1970年 | 4篇 |
1969年 | 3篇 |
1968年 | 3篇 |
1966年 | 3篇 |
排序方式: 共有1703条查询结果,搜索用时 6 毫秒
21.
22.
Building workforce capacity for ethical reflection in health promotion: a practitioner's experience 下载免费PDF全文
Health promotion does not have a code of ethics, although attempts have been made to assist practitioners in their understanding and application of ethical concepts. This article describes and analyses one such attempt, sustained from 2006 to 2014 in rural South Australia. The attempt comprised capacity‐building activities that were informed by principles of organisational change management, especially the principle of creating champions. The article also presents a framework (largely comprising ethical questions) that may help practitioners as a prompt and guide to ethical reflection. The framework was developed to be as accessible as possible in light of the diverse educational backgrounds found in rural settings. Finally, the article highlights some philosophical dimensions to the framework and defends its role, proposing that ethical reflection is integral to good practice and never simply the province of theorists. The article does all this with a view to stimulating discussion on how to increase the frequency and quality of ethical reflection undertaken by health promotion practitioners. 相似文献
23.
24.
Ronghe MD Foot AB Cornish JM Steward CG Carrington D Goulden N Marks DI Oakhill A 《British journal of haematology》2002,118(4):1124-1127
The impact of transfusion of leucodepleted platelet concentrates (PCs) on cytomegalovirus (CMV) disease was assessed in 215 allogeneic (145 unrelated and 70 related donor) transplants over 3 years. In 43%, both donor and patient were CMV seronegative (CMV-/-). All received CMV-seronegative red cells and random leucodepleted PCs. No CMV disease occurred in any CMV-/- (low risk) transplant. CMV infection occurred in 31 seropositive patients (26%); 13 died and five deaths were attributable to CMV disease. When compared with historical controls, who received CMV-seronegative PCs, we found no difference in transfusion-acquired CMV in the current cohort. 相似文献
25.
Morphology of the uvula in obstructive sleep apnea 总被引:12,自引:0,他引:12
J L Stauffer M K Buick E O Bixler F E Sharkey A B Abt E K Manders A Kales R J Cadieux J D Barry C W Zwillich 《The American review of respiratory disease》1989,140(3):724-728
Alterations in pharyngeal structure and function are considered fundamental in the pathogenesis of obstructive sleep apnea (OSA). However, little is known about morphologic features of the pharynx in patients with OSA. We therefore studied the tissue composition of the uvula (midsagittal section) in patients with OSA, using a quantitative, morphometric point-counting technique. Uvula tissue was obtained by uvulopalatopharyngoplasty (UPPP) in 33 patients (mean number of apneas per hour of sleep = 32.7 +/- 5.2) and by autopsy in 22 normal subjects not known to have OSA. All statistical comparisons were controlled for differences caused by age and body mass index. Patients with OSA had a significantly greater percentage of muscle in the uvula (18.1 +/- 1.9% versus 9.3 +/- 2.1%, p = 0.02) than did normal subjects. A significant difference in fat content was also found (9.5 +/- 1.4% in patients versus 4.0 +/- 1.0% in normal subjects, p less than 0.02). These differences between patients with OSA and control subjects could not be accounted for by anthropometric or sex differences. The percentage of uvula fat tissue was significantly related to the frequency of apneas and hypopneas in sleep (r = 0.43, p less than 0.01). Uvula morphology in 6 nonapneic snorers undergoing UPPP was similar to that of patients with OSA. We conclude that the uvula in patients with OSA contains more muscle and fat than the uvula in control subjects, possibly contributing to pharyngeal narrowing in OSA. 相似文献
26.
Prevalence of malnutrition,obesity and nutritional risk of Australian paediatric inpatients: A national one‐day snapshot 下载免费PDF全文
27.
Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome 总被引:45,自引:0,他引:45
Coates MD Mahoney CR Linden DR Sampson JE Chen J Blaszyk H Crowell MD Sharkey KA Gershon MD Mawe GM Moses PL 《Gastroenterology》2004,126(7):1657-1664
BACKGROUND & AIMS: Serotonin (5-HT) is a critical signaling molecule in the gut. 5-HT released from enterochromaffin cells initiates peristaltic, secretory, vasodilatory, vagal, and nociceptive reflexes. Despite being pathophysiologically divergent, ulcerative colitis (UC) and irritable bowel syndrome (IBS) are both associated with clinical symptoms that include alterations in the normal patterns of motility, secretion, and sensation. Our aim was to test whether enteric 5-HT signaling is defective in these disorders. METHODS: Rectal biopsy specimens were obtained from healthy controls and patients with UC, IBS with diarrhea (IBS-D), and IBS with constipation (IBS-C). Key elements of 5-HT signaling, including measures of 5-HT content, release, and reuptake, were analyzed with these samples. RESULTS: Mucosal 5-HT, tryptophan hydroxylase 1 messenger RNA, serotonin transporter messenger RNA, and serotonin transporter immunoreactivity were all significantly reduced in UC, IBS-C, and IBS-D. The enterochromaffin cell population was decreased in severe UC samples but was unchanged in IBS-C and IBS-D. When 5-HT release was investigated under basal and mechanical stimulation conditions, no changes were detected in any of the groups relative to controls. CONCLUSIONS: These data show that UC and IBS are associated with similar molecular changes in serotonergic signaling mechanisms. While UC and IBS have distinct pathophysiologic properties, these data suggest that shared defects in 5-HT signaling may underlie the altered motility, secretion, and sensation. These findings represent the first demonstration of significant molecular alterations specific to the gut in patients with IBS and support the assertion that disordered gastrointestinal function in IBS involves changes intrinsic to the bowel. 相似文献
28.
C M Keenan M A Storr G A Thakur J T Wood J Wager-Miller A Straiker M R Eno S P Nikas M Bashashati H Hu K Mackie A Makriyannis K A Sharkey 《British journal of pharmacology》2015,172(9):2406-2418
Background and Purpose
Cannabinoid (CB) ligands have been demonstrated to have utility as novel therapeutic agents for the treatment of pain, metabolic conditions and gastrointestinal (GI) disorders. However, many of these ligands are centrally active, which limits their usefulness. Here, we examine a unique novel covalent CB receptor ligand, AM841, to assess its potential for use in physiological and pathophysiological in vivo studies.Experimental Approach
The covalent nature of AM841 was determined in vitro using electrophysiological and receptor internalization studies on isolated cultured hippocampal neurons. Mouse models were used for behavioural analysis of analgesia, hypothermia and hypolocomotion. The motility of the small and large intestine was assessed in vivo under normal conditions and after acute stress. The brain penetration of AM841 was also determined.Key Results
AM841 behaved as an irreversible CB1 receptor agonist in vitro. AM841 potently reduced GI motility through an action on CB1 receptors in the small and large intestine under physiological conditions. AM841 was even more potent under conditions of acute stress and was shown to normalize accelerated GI motility under these conditions. This compound behaved as a peripherally restricted ligand, showing very little brain penetration and no characteristic centrally mediated CB1 receptor-mediated effects (analgesia, hypothermia or hypolocomotion).Conclusions and Implications
AM841, a novel peripherally restricted covalent CB1 receptor ligand that was shown to be remarkably potent, represents a new class of potential therapeutic agents for the treatment of functional GI disorders. 相似文献29.
30.